Ever Fortune. AI Co

Ever Fortune. AI Co Operating Cash Flow

The Operating Cash Flow of Ever Fortune. AI Co (6841.TWO) as of Oct 21, 2026 is 46.77 M TWD. In the previous year, Operating Cash Flow was 62.51 M TWD — a change of -25.19% (lower).

Operating Cash Flow

46.77 MTWD

YoY

-25.19%

Last updated:

Operating Cash Flow of Ever Fortune. AI Co is 2025 46.77 M TWD. Operating Cash Flow of Ever Fortune. AI Co was 2024 62.51 M TWD. It decreases by -25.19% lower compared to the previous year.

The Ever Fortune. AI Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-2.20 M TWD
Jan 1, 2019
-40.93 M TWD
Jan 1, 2020
-39.19 M TWD
Jan 1, 2021
-41.92 M TWD
Jan 1, 2022
-60.43 M TWD
Jan 1, 2023
-27.60 M TWD
Jan 1, 2024
62.51 M TWD
Jan 1, 2025
46.77 M TWD
The Ever Fortune. AI Co Operating Cash Flow history
YEAROperating Cash FlowYoY
46.77 MTWD-25.19%
62.51 MTWD-326.48%
-27.60 MTWD-54.32%
-60.43 MTWD+44.16%
-41.92 MTWD+6.96%
-39.19 MTWD-4.24%
-40.93 MTWD+1,761.92%
-2.20 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ever Fortune. AI Co Stock analysis

What does Ever Fortune. AI Co do? Ever Fortune.AI Co., Ltd. generates revenue through the sale of medical AI software products and customized technology solutions. The company offers medical big data platforms, cloud biomedical services, and AI-driven tools such as the radiographic bone age-assisted interpretation system, ultrasound breast tumor auxiliary classification system, and CT liver cancer metastasis risk management system. These products target healthcare providers, hospitals, and medical institutions seeking advanced diagnostic and analytical capabilities. The firm's focus on specialized medical AI applications ensures consistent demand from clients requiring precision in radiology, oncology, and cardiology. The company's revenue streams include the provision of medical AI data analysis services and tailored AI technology solutions for healthcare facilities. Products like the liver fibrosis evaluation system and irregular cardiac fibrillation interpretation system are designed to address specific clinical needs, enhancing diagnostic accuracy. Healthcare organizations, particularly those in radiology and cardiology departments, purchase these tools to improve patient outcomes and operational efficiency. Ever Fortune.AI's business model centers on delivering high-value AI solutions for medical diagnostics, with a portfolio that includes both standardized products and custom-developed systems. The firm's offerings cater to hospitals and medical institutions looking to integrate AI into their diagnostic workflows. By focusing on niche medical applications, the company establishes itself as a specialized provider in the healthcare technology sector. Ever Fortune. AI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Fortune. AI Co stock

Operating Cash Flow of Ever Fortune. AI Co is 46.77 M TWD in 2025.

Operating Cash Flow of Ever Fortune. AI Co changed from 62.51 M TWD to 46.77 M TWD, representing a -25.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Ever Fortune. AI Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Ever Fortune. AI Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ever Fortune. AI Co

All Key Metrics — Ever Fortune. AI Co